ProTrials in the Top Ten Women-Owned Businesses in Silicon Valley
ProTrials Research, Inc.TM, a leader in the clinical research organization industry, announced the Silicon Valley/San Jose Business Journal has chosen it as one of the area?s Top 50 Women-Owned Businesses for 2008. ProTrials placed seventh on the list that ranks area public and private women-owned companies according to revenue.
ProTrials Cracks the Top Ten in Silicon Valley’s Women-Owned Businesses Ranking
Company jumps to seventh based on increased revenues
Mountain View, CA – July 16, 2008 – ProTrials Research, Inc.TM, a leader in the clinical research organization industry, today announced the Silicon Valley/San Jose Business Journal has chosen it as one of the area’s Top 50 Women-Owned Businesses for 2008. ProTrials placed seventh on the list that ranks area public and private women-owned companies according to revenue.
“Jumping from number nine on last year’s list to seventh this year correlates to ProTrials’ accelerated business momentum and its ability to achieve significant milestones,” commented Jodi Andrews, ProTrials co-founder and CEO. “Our commitment to providing the best clinical trial services to our clients is key to this growth, and has resulted in higher visibility and increased sales. We are pleased that the Silicon Valley/San Jose Business Journal continues to recognize ProTrials’ success.”
ProTrials is the only clinical research organization to make the Silicon Valley/San Jose Business Journal top 50 and is one of only a handful of women-owned and operated CROs worldwide. It recently attained certification by the Women’s Business Enterprise National Council, an elite group of women-owned and operated businesses. In 2007, ProTrials achieved a ranking on the Inc. 5000, a list that recognizes the fastest-growing private companies in the United States.
About ProTrials Research, Inc.
Founded in 1996, ProTrials Research, Inc. is a specialized clinical research organization (CRO) with regional clinical research associates and project managers based throughout North America, Canada, and Europe. The company works with clients in the pharmaceutical, biotechnology and medical device industries, providing cost-effective site monitoring, project management and associated clinical operations services. ProTrials is headquartered in Mountain View, California. For more information, visit www.protrials.com <http://www.protrials.com/> or call (650) 864-9180.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
